James Paul Scopa, Director at Conatus Pharmaceuticals Inc (CNAT), bought 1,192,080 shares at $11.00 ($2.0M) on 2013-07-30, disclosed to the SEC on 2013-08-01.
Open-market purchase of $2.0M CNAT by Director. Below the thresholds we flag for high-conviction alerts (no C-suite role, rare reversal, cluster, or A-grade history).
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $0.00 | 1,010,099 | $0 | 0.0% |
| 2 | $11.00 | 16,716 | $184K | 9.2% |
| 3 | $11.00 | 165,265 | $1.8M | 90.8% |
| Total | $1.68 avg | 1,192,080 | $2.0M | 100% |
| Filing → |
| ADVM | SELL | 2021-11-17 | $218K | — | Filing → |
| DICE | BUY | 2021-09-16 | $102K | — | Filing → |
| ADVM | BUY | 2020-02-14 | $138K | — | Filing → |